Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oropharyngeal Neoplasms | 5 | 2022 | 165 | 0.920 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.860 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2023 | 55 | 0.830 |
Why?
|
| Carcinoma | 1 | 2023 | 287 | 0.710 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2022 | 101 | 0.530 |
Why?
|
| Hemangiosarcoma | 2 | 2014 | 41 | 0.490 |
Why?
|
| Splenic Neoplasms | 1 | 2014 | 12 | 0.440 |
Why?
|
| Leukocytosis | 1 | 2014 | 46 | 0.430 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 226 | 0.380 |
Why?
|
| Anemia | 1 | 2014 | 339 | 0.330 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 183 | 0.330 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 178 | 0.320 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2011 | 146 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 668 | 0.310 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 119 | 0.300 |
Why?
|
| Lung | 2 | 2011 | 1496 | 0.260 |
Why?
|
| Fatal Outcome | 3 | 2014 | 359 | 0.240 |
Why?
|
| Influenza, Human | 1 | 2011 | 662 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 296 | 0.230 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2005 | 26 | 0.230 |
Why?
|
| Gingiva | 1 | 2023 | 9 | 0.220 |
Why?
|
| Gene Fusion | 1 | 2023 | 55 | 0.210 |
Why?
|
| Lymphatic Metastasis | 1 | 2023 | 418 | 0.200 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 762 | 0.190 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 210 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 358 | 0.180 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 503 | 0.170 |
Why?
|
| Thrombosis | 1 | 2005 | 526 | 0.170 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 897 | 0.160 |
Why?
|
| Fibroblasts | 3 | 2016 | 888 | 0.150 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1275 | 0.150 |
Why?
|
| Deglutition Disorders | 1 | 2019 | 131 | 0.140 |
Why?
|
| Semaphorins | 1 | 2016 | 29 | 0.130 |
Why?
|
| Biomarkers, Tumor | 2 | 2023 | 1496 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1438 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 1360 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 291 | 0.120 |
Why?
|
| Middle Aged | 8 | 2019 | 26920 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 239 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 723 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2016 | 238 | 0.120 |
Why?
|
| Skin | 2 | 2010 | 519 | 0.120 |
Why?
|
| HLA-DRB1 Chains | 1 | 2014 | 38 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 103 | 0.110 |
Why?
|
| Protein Transport | 1 | 2016 | 368 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 2107 | 0.110 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 48 | 0.110 |
Why?
|
| Prognosis | 3 | 2022 | 4644 | 0.110 |
Why?
|
| Humans | 17 | 2023 | 125128 | 0.100 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 287 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2016 | 558 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2016 | 1140 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 816 | 0.100 |
Why?
|
| Male | 12 | 2019 | 61501 | 0.100 |
Why?
|
| Genotype | 2 | 2016 | 2565 | 0.100 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2011 | 20 | 0.090 |
Why?
|
| Biocatalysis | 1 | 2011 | 34 | 0.090 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 663 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 691 | 0.090 |
Why?
|
| Osteonectin | 1 | 2010 | 6 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 1265 | 0.080 |
Why?
|
| Adult | 7 | 2018 | 29611 | 0.080 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 109 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2011 | 676 | 0.080 |
Why?
|
| Aged | 6 | 2019 | 19870 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 2048 | 0.070 |
Why?
|
| Veterans | 2 | 2015 | 1748 | 0.070 |
Why?
|
| Fenretinide | 1 | 2005 | 16 | 0.060 |
Why?
|
| HIV Infections | 1 | 2018 | 1899 | 0.060 |
Why?
|
| Female | 10 | 2019 | 66781 | 0.060 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2005 | 60 | 0.060 |
Why?
|
| Catastrophic Illness | 1 | 2005 | 3 | 0.060 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2005 | 19 | 0.060 |
Why?
|
| Vascular Neoplasms | 1 | 2005 | 32 | 0.060 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 155 | 0.060 |
Why?
|
| Skin Ulcer | 1 | 2005 | 33 | 0.060 |
Why?
|
| Microcirculation | 1 | 2005 | 96 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 10314 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2005 | 363 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 3157 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2005 | 141 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 443 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2022 | 144 | 0.050 |
Why?
|
| Smoking | 2 | 2015 | 1051 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2022 | 319 | 0.040 |
Why?
|
| Transfection | 2 | 2011 | 1069 | 0.040 |
Why?
|
| Gene Expression | 2 | 2016 | 1560 | 0.040 |
Why?
|
| Gastrostomy | 1 | 2019 | 86 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2005 | 1527 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 78 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 115 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 1691 | 0.030 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2016 | 10 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 25 | 0.030 |
Why?
|
| Silicon Dioxide | 1 | 2016 | 24 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 145 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2016 | 108 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 1711 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 10 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3348 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 314 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1693 | 0.030 |
Why?
|
| Carcinogens | 1 | 2015 | 152 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 50 | 0.030 |
Why?
|
| China | 1 | 2014 | 246 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 620 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 847 | 0.030 |
Why?
|
| Hospitals, Veterans | 1 | 2015 | 359 | 0.030 |
Why?
|
| Alcoholism | 1 | 2015 | 231 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1056 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 346 | 0.020 |
Why?
|
| Diet | 1 | 2019 | 1140 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2015 | 1506 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3146 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 37 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 198 | 0.020 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 19 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2010 | 112 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5176 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2010 | 123 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2311 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2010 | 108 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 506 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2016 | 1502 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 236 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 1102 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1290 | 0.020 |
Why?
|
| Fibrosis | 1 | 2010 | 436 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2015 | 16348 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2637 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 17633 | 0.020 |
Why?
|
| Texas | 1 | 2015 | 3588 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 4811 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2015 | 3465 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 77 | 0.020 |
Why?
|
| Clone Cells | 1 | 2005 | 166 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2397 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2010 | 3056 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2002 | 36 | 0.010 |
Why?
|
| Animals | 2 | 2016 | 34235 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2018 | 12391 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 462 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 781 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4405 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 4395 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1898 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 1894 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2005 | 2513 | 0.010 |
Why?
|